3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Mesothelioma
3
Neoplasms
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Medical Oncology
1
Lung Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
28
pembrolizumab
24
Cisplatin
24
Fluorouracil
11
Leucovorin
10
Oxaliplatin
8
Nivolumab
7
Capecitabine
6
Irinotecan
5
Drug Therapy
5
pemigatinib
4
futibatinib
4
Paclitaxel
4
Carboplatin
4
ivosidenib
3
durvalumab
3
derazantinib
3
Folfox protocol
3
Bevacizumab
3
zanidatamab
2
spartalizumab
2
olutasidenib
2
lenvatinib
2
infigratinib
2
fludarabine
2
budigalimab
2
Trastuzumab
2
Ipilimumab
2
Injections
2
Docetaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Cholangiocarcinoma
×
anetumab ravtansine
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled